Compass Pathways (NASDAQ: CMPS), a leading developer in psychedelic therapy, stands at the forefront of innovative treatments for mood disorders. This makes it an exciting, albeit high-risk, investment opportunity. However, the potential for substantial returns is significant, especially with two major catalysts on the horizon that could alleviate much of the associated risk and potentially ..read more

The Alaska legislature has approved a bill to create a task force dedicated to preparing the state for the potential federal legalization of psychedelic therapies. Introduced by Representative Jennie Armstrong, an Anchorage Democrat, the bill passed on May 10. The task force will not advocate for or against the use of psychedelic treatments but will ..read more

VANCOUVER, British Columbia, May 22, 2024 (GLOBE NEWSWIRE) — Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading Health Canada licensed psychedelics pharmaceutical manufacturer, specializing in controlled substances such as botanical psilocybin and MDMA, has entered a Letter of Intent (LOI) with ATMA Journey Centers (ATMA). ATMA is a pioneering Canadian firm focused on advancing ..read more

On this episode of the Psychedelic Invest Podcast, host Bruce Eckfeldt is joined by Kimberly Chew, Senior Counsel at Husch Blackwell. Kimberly is a seasoned legal professional with a rich background in biotech research, leveraging her extensive experience to guide clients through the intricate landscape of clinical trials and academic research compliance. On this episode ..read more

Toronto, Ontario–(Newsfile Corp. – May 23, 2024) – PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) (“PharmaDrug” or the “Company“), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances, natural medicines, and previously approved drugs, is pleased to announce that the Company’s wholly-owned subsidiary, Securedose Synthetics Inc. (“SecureDose”) has signed an Letter of Intent ..read more

Vancouver, Canada, May 07, 2024 (GLOBE NEWSWIRE) —  Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announces the signing of an exclusive patent licensing agreement with Yissum Research Development Company of the Hebrew University of Jerusalem. This agreement ..read more

NEW YORK–(BUSINESS WIRE)– Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced its financial results for the quarter ended March 31, 2024, and provided a business update. “Building on a highly productive 2023, we were pleased to start ..read more

On June 4th, the U.S. FDA’s panel of independent advisers will convene to discuss the potential approval of the first MDMA-assisted therapy for post-traumatic stress disorder (PTSD), announced Lykos Therapeutics on Monday. This marks a significant milestone as it is the first time in 25 years that an FDA panel will review a new treatment ..read more

VANCOUVER, British Columbia, May 09, 2024 (GLOBE NEWSWIRE) — Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading Health Canada licensed GMP psychedelics pharmaceutical manufacturer, specializing in controlled substances such as botanical psilocybin and MDMA, is pleased to report a significant update to its collaboration with The Institute for Psychedelic Research at Tel Aviv University ..read more

Researchers from Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today presented new studies highlighting the significant impact of GAD in the US at ISPOR 2024, the leading global conference for health economics and outcomes research (HEOR) being held this week ..read more